Successful trials yielding partnerships is obviously paramount. Private placement with known successful biotech investors (angels) would be next followed by PP with private unknown investors and Aspire must be considered better than nothing but is not optimal for investors in the current environment. Trial results therefore trump every other possibility. Not long to wait for B-OM.
Market Data 
Markets 
AI
